Tarlatamab

New research in 'Oncotarget' identifies DLL3 and TTF-1 as promising biomarkers for personalized SCLC treatment, potentially improving patient outcomes through precision medicine.

Study of 64 SCLC patients reveals DLL3 in 70% of tumors, potential for Tarlatamab; TTF-1-positive tumors show better survival, suggesting prognostic value. Digital pathology tools enhance analysis, supporting precision medicine in SCLC.

Tarlatamab, from the DeLLphi-301 study, showed durable responses (median PFS 4.3 months, median duration of response 9.7 months) and a favorable safety profile, leading to FDA accelerated approval in May 2024 for relapsed/refractory SCLC. Early toxicities, mainly cytokine release syndrome, were manageable and diminished over time, with no late-onset toxicities observed.

Himisha Beltran discusses DLL3 as a target for neuroendocrine prostate cancer treatment, highlighting its high expression in neuroendocrine and small cell prostate cancers. She reviews clinical trials of DLL3-targeted T-cell engagers like Tarlatamab and MK-6070, emphasizing the importance of patient selection and addressing tumor heterogeneity. Beltran also explores the need for better biomarkers and imaging techniques, and the potential for combination therapies to treat mixed tumor populations.

Virginia cancer centers offer advanced care, including NCI-designated comprehensive centers, updated technology, and expanding facilities, ensuring patients need not travel out of state for treatment.

Amgen presents new data on IMDELLTRA™ (tarlatamab-dlle), a DLL3-targeting BiTE® molecule, at the 2024 WCLC, highlighting its efficacy in extensive-stage small cell lung cancer (ES-SCLC) as both a monotherapy and in combination with PD-L1 inhibitors.

Heavily pretreated ES-SCLC patients benefited from ifinatamab deruxtecan (I-DXd), with a 12 mg/kg dose showing higher overall response rate (54.8%) vs. 8 mg/kg (26.1%). Disease control rates were over 80% in both groups, suggesting I-DXd's potential as a treatment option for ES-SCLC.

Extended follow-up of DeLLphi-300 trial shows tarlatamab, a bispecific T-cell engager, benefits previously treated small cell lung cancer patients with 25.0% objective response rate, 11.2 months median duration of response, and 17.5 months median overall survival. At recommended 10 mg every 2 weeks, 35.3% response rate, 14.9 months median duration, 20.3 months median survival, and 29.4% sustained disease control at ≥ 52 weeks. Intracranial activity observed in 62.5% with baseline CNS lesions ≥ 10 mm.

Bispecific antibodies, with two binding domains, offer targeted therapeutics and address co-administration challenges, gaining traction in biopharma. Initially approved for cancer, they now target various diseases, with 12 approved in the U.S. and more in development. Their dual action reduces patient burden and enhances treatment effects, potentially transforming therapeutic paradigms beyond oncology. The market is projected to grow significantly due to rising chronic disease incidence and technological advancements.